Table 3.

Summary of FDA-approved DNMT inhibitor involved against cancer therapy.

Epigenetic Drug	FDA Approved	Clinical Trial Phase	NCT Number	Deseas
5-azacytidine	✓	I, I, II	NCT02940483 NCT00886457 NCT00744757	Brain tumor recurrent cancer Myelodysplastic syndrome
decitabine	✓	I	NCT04252248	Head and neck cancer Anogenital cancer